Illustrative image.
Dovato
Dolutegravir/Lamivudine
$3540.00
50/300mg · 3 × 30 tablets · 3 months supply
BrandBranded medicine· By GSK
$1180.00 per month
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$14160a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningPatients co-infected with hepatitis b virus (hbv) and human immunodeficiency virus (hiv-1): emergence of lamivudine-resistant hbv and exacerbations of hbv
All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.
Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment.
About Dovato
Overview
Dovato is a tablet combining two HIV-1 medicines, dolutegravir and lamivudine. It is a complete treatment for HIV-1 infection in adults and adolescents aged 12 years and older who weigh at least 25 kg. It is used in people who have never taken HIV treatment, or to replace stable treatment when HIV-1 levels are below 50 copies/mL, with no history of treatment failure or known resistance to either ingredient. Its ingredients block two different HIV-1 targets: integrase and reverse transcriptase.
What it treats
Dovato is used to treat HIV-1 infection in adults and adolescents aged 12 years and older who weigh at least 25 kg. It is a complete treatment regimen for those who: - Have not previously received antiretroviral treatment; or - Are switching from a stable antiretroviral regimen with HIV-1 levels below 50 copies/mL, no history of treatment failure and no known resistance to either dolutegravir or lamivudine.
Safety information
Side effects
Common side effects of Dovato include headache, nausea, diarrhoea, trouble sleeping, tiredness and anxiety. Serious side effects include: • Severe allergic reactions, which may involve a rash, feeling unwell and organ problems, including liver injury. Stop taking Dovato and seek medical help immediately if signs of an allergic reaction develop. Delaying stopping treatment may lead to a life-threatening reaction. • Liver injury. People with hepatitis B or C may be at greater risk of raised liver enzymes or worsening elevations. Monitoring for liver injury is recommended. • Lactic acidosis (a build-up of lactic acid) and severe liver enlargement with fat accumulation. Fatal cases have been reported with medicines in the nucleoside analogue class. • Immune reconstitution syndrome, which has been reported with combination HIV treatment. Contact a doctor promptly if you suspect a serious side effect.
FDA boxed warning
Patients co-infected with hepatitis b virus (hbv) and human immunodeficiency virus (hiv-1): emergence of lamivudine-resistant hbv and exacerbations of hbv
All patients with HIV-1 should be tested for the presence of HBV prior to or when initiating DOVATO. Emergence of lamivudine-resistant HBV variants associated with lamivudine-containing antiretroviral regimens has been reported. If DOVATO is used in patients co-infected with HIV-1 and HBV, additional treatment should be considered for appropriate treatment of chronic HBV; otherwise, consider an alternative regimen.
Severe acute exacerbations of HBV have been reported in patients who are co-infected with HIV-1 and HBV and have discontinued lamivudine, a component of DOVATO. Closely monitor hepatic function in these patients and, if appropriate, initiate anti-HBV treatment.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not take Dovato if you have previously had an allergic reaction to dolutegravir or lamivudine, or if you take dofetilide. Dovato can increase dofetilide levels and cause serious or life-threatening effects. Dovato is not recommended for people with kidney function measured as creatinine clearance below 30 mL/min or severe liver impairment (Child-Pugh class C). Liver injury has been reported. People with hepatitis B or C may have a higher risk of raised liver enzymes; monitoring for liver injury is recommended. Stop Dovato immediately and seek urgent medical attention if signs of an allergic reaction develop, such as a rash with other symptoms of illness. These reactions can involve the liver or other organs and may be life-threatening. Other serious risks reported include lactic acidosis (a build-up of lactic acid in the blood), severe liver enlargement with fat accumulation, and immune reconstitution syndrome, in which the recovering immune system causes an inflammatory response.
Interactions
Dovato is a complete treatment regimen for HIV-1. Taking it with other antiretroviral medicines used to treat HIV-1 is not recommended. Discuss any other HIV medicines you take with your doctor. The full prescribing information contains further important drug interaction details.
Using Dovato
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label DOVATO (DOLUTEGRAVIR SODIUM AND LAMIVUDINE) TABLET, FILM COATED [VIIV HEALTHCARE COMPANY] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Ziagen
Abacavir
By GSK
Tablets · from 60 per pack
Also for antivirals
Brand $767.00
Baraclude
Enetecavir
By Bristol Myers
Tablets · from 30 per pack
Also for antivirals
Brand from $1,203.00
Isenrtess
Raltegravir
By MSD
Tablets · from 60 per pack
Also for antivirals
Brand $1,398.00
STRIBILD
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate
By Gilead Sciences
Tablets · from 30 per pack
Also for antivirals
Brand $1,405.00